

UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 11, 2020

**Safeguard Scientifics, Inc.**

(Exact Name of registrant as Specified in Charter)

**Pennsylvania**  
(State or other Jurisdiction of Incorporation)

**1-5620**  
(Commission File Number)

**23-1609753**  
(IRS Employer ID No.)

**One Radnor Corp. Ctr., Suite 110**  
**100 Matsonford Rd.**  
**Radnor, PA**  
(Address of Principal Executive Offices)

**19087**  
(Zip Code)

Registrant's telephone number, including area code: **610-293-0600**

**Not applicable**

(Former Name or Former Address if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock (\$.10 par value)	SFE	New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**ITEM 7.01. Regulation FD Disclosure.**

On August 11, 2020, during the prepared remarks of the quarterly earnings call of Safeguard Scientifics, Inc. (the “Company”), the Company stated that one of the Company’s portfolio companies is under a letter of intent with a prospective private equity buyer, while another of the Company’s portfolio companies will soon launch a sale process after having selected a financial advisor to assist it with the process. During the question and answer portion of the quarterly earnings call, the Company inadvertently stated in response to a question that two of the Company’s portfolio companies are under letters of intent, rather than one. In fact, as initially stated during the prepared remarks of the call, one portfolio company is under a letter of intent for a sale, and a second portfolio company will soon launch a sale process.

**ITEM 9.01. Financial Statements and Exhibits.**

(d) Exhibits.

104 Cover Page Interactive Data File (formatted as Inline XBRL).

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

### **Safeguard Scientifics, Inc.**

Date: August 12, 2020

By: /s/ G. Matthew Barnard

Name: G. Matthew Barnard

Title: General Counsel